Bain Capital Life Sciences specializes in buyouts, inflection capital, growth capital, turnaround investments, and private equity.
Bain Capital Life Sciences specializes in buyouts, inflection capital, growth capital, turnaround investments, and private equity. It invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of the Bain Capital Life Sciences team enables it to deliver targeted capital and value-added strategic support to companies around critical phases of growth and inflections in value.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 15, 2022
Jnana Therapeutics
|
Series C | $107M | Biotechnology | Yes |
Sep 12, 2022
Nimbus Therapeutics
|
Series Unknown | $125M | Biotechnology | — |
Jul 12, 2022
Areteia Therapeutics
|
Series A | $350M | Biotechnology | Yes |
Jun 30, 2022
X4 Pharmaceuticals
|
Post-IPO Equity | $55M | Biotechnology | — |
Dec 7, 2021
Freenome
|
Series D | $300M | Biotechnology | — |